Amplion, a Bend, Ore,-based life sciences knowledge intelligence firm, is being acquired by knowledge and publishing firm Science and Drugs Group (SMG).
Phrases of the sale of Amplion’s property to Arlington, Va.-based SMG weren’t disclosed Wednesday.
“SMG approached Amplion as we have been scouting for top of the range property that would assist us to construct the premier knowledge intelligence firm and supply insights about hard-to-reach audiences in life sciences and healthcare,” Ed Burnham, head of market analysis and analytics at SMG, instructed Startup. Burnham is now main the Amplion enterprise at SMG.
Amplion’s software program sifts via firm data and public databases like PubMed.gov and ClinicalTrials.gov for knowledge that can be utilized by industrial clients to help gross sales, advertising and marketing and enterprise growth. It additionally sells BiomarkerBase, which pulls out data on biomarkers, molecules that point out illnesses and different organic states, comparable to which of them are related to scientific trials.
BiomarkerBase is not actively marketed, Burnham instructed Startup, however SMG will proceed to promote it as a part of its portfolio of life science merchandise. SMG offers market analysis providers and publishes websites like DrBicuspid for dental professionals and LabPulse, for specialists in lab software program, molecular diagnostics, and different fields. SMG has greater than 120 staff.
Amplion was based 10 years in the past by biotech vets John Audette, who left the corporate in 2016, and Adam Carroll, previously the corporate’s chief scientific officer, who additionally departed.
Amplion CEO Chris Capdevila will stay as a marketing consultant and Amplion’s 9 staff and contractors may even keep on, stated Burnham. Amplion beforehand raised an undisclosed quantity in a Collection A funding spherical and gained $400,000 as a part of a contest at Bend Enterprise Convention.
“Science and Drugs Group’s clients now have entry to a purpose-built, machine studying platform for all times science industrial groups, whereas Amplion’s clients are assured of continued help and long-term funding from a well-established firm to additional improve the platform’s capabilities,” Burnham stated in an announcement saying the deal.